Adverum Biotechnologies, Inc. (ADVM)

NASDAQ: ADVM · IEX Real-Time Price · USD
1.770
+0.070 (4.12%)
At close: Mar 18, 2024, 4:00 PM
1.620
-0.150 (-8.47%)
After-hours: Mar 18, 2024, 7:59 PM EDT
4.12%
Market Cap 362.54M
Revenue (ttm) 3.60M
Net Income (ttm) -117.17M
Shares Out 207.16M
EPS (ttm) -1.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,411,305
Open 1.720
Previous Close 1.700
Day's Range 1.655 - 1.790
52-Week Range 0.681 - 2.970
Beta 0.87
Analysts Strong Buy
Price Target 4.00 (+125.99%)
Earnings Date Mar 18, 2024

About ADVM

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 31, 2014
Employees 123
Stock Exchange NASDAQ
Ticker Symbol ADVM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ADVM stock is "Strong Buy." The 12-month stock price forecast is $4.0, which is an increase of 125.99% from the latest price.

Price Target
$4.0
(125.99% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

- Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet AMD -

6 hours ago - GlobeNewsWire

Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference

REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly p...

19 days ago - GlobeNewsWire

Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

REDWOOD CITY, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...

5 weeks ago - GlobeNewsWire

Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD

– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic...

5 weeks ago - GlobeNewsWire

Adverum Biotechnologies Announces $127.5 Million Private Placement Financing

- Financing led by TCGX with participation from new and existing investors including 5AM Ventures, Commodore Capital, Frazier Life Sciences, Logos Capital, Samsara BioCapital, Venrock Healthcare Capit...

6 weeks ago - GlobeNewsWire

Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

- Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47 th Annual Meeting of the Macula Society, with company-sponsor...

6 weeks ago - GlobeNewsWire

Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer

REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...

7 weeks ago - GlobeNewsWire

Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...

3 months ago - GlobeNewsWire

Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference

REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...

3 months ago - GlobeNewsWire

Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights

- Announced preliminary aflibercept protein levels from the on-going Phase 2 LUNA trial, suggesting that both doses are within the therapeutically active range and consistent with aflibercept levels o...

4 months ago - GlobeNewsWire

Adverum Biotechnologies Appoints C. David Nicholson, Ph.D.

REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...

4 months ago - GlobeNewsWire

Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023

- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction i...

4 months ago - GlobeNewsWire

Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial

- Initial aflibercept protein levels in LUNA suggest Ixo-vec at both the 2E11 and 6E10 doses delivers aflibercept protein levels within the therapeutically active range -

6 months ago - GlobeNewsWire

Adverum Biotechnologies to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly...

6 months ago - GlobeNewsWire

Adverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

REDWOOD CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly...

6 months ago - GlobeNewsWire

Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officer

Dr. Ramelmeier has more than 30 years of experience in drug development and clinical and commercial chemistry, manufacturing and controls (CMC), including gene and cell therapies Dr. Ramelmeier has mo...

7 months ago - GlobeNewsWire

Adverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

REDWOOD CITY, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...

7 months ago - GlobeNewsWire

Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results

- LUNA 14-week data on aflibercept protein levels anticipated in the third quarter of 2023 and preliminary efficacy and safety data anticipated in the fourth quarter of 2023 -

7 months ago - GlobeNewsWire

Adverum Biotechnologies Grants License to Ray Therapeutics Inc. for the AAV.7m8 Intravitreal Capsid

Adverum has granted Ray Therapeutics a non-exclusive, royalty-bearing license for the use of Adverum's proprietary intravitreal AAV.7m8 vector capsid together with RayTx's RTx-015 asset Adverum has gr...

10 months ago - GlobeNewsWire

Adverum Biotechnologies to Participate in the Jefferies Healthcare Conference

REDWOOD CITY, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...

10 months ago - GlobeNewsWire

Adverum Biotechnologies Announces New Executive Leadership Roles

- Richard Beckman, M.D., chief medical officer, transitions to senior medical advisor - - Star Seyedkazemi, Pharm.D.

10 months ago - GlobeNewsWire

Adverum Biotechnologies Presents Nonclinical Data in Support of Ixo-vec's Phase 2 Clinical Development at ASGCT 2023 Annual Meeting

REDWOOD CITY, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly p...

10 months ago - GlobeNewsWire

Adverum Biotechnologies Introduces an Intravitreal Gene Therapy Program for Geographic Atrophy and Presents Data on Its Ocular Gene Therapy Platform

- Geographic atrophy (GA) program introduced with complement Factor I (CFI), a key component of the complement cascade, as a payload and utilizing two intravitreal (IVT) capsids, 7m8 and LSV1 -

10 months ago - GlobeNewsWire

Adverum Biotechnologies Reports First Quarter 2023 Financial Results

- Full enrollment of the Phase 2 LUNA trial in wet age-related macular degeneration (wet AMD) is anticipated in the second half of 2023 -

11 months ago - GlobeNewsWire

Adverum Biotechnologies to Participate in RBC Capital Markets Global Healthcare Conference

REDWOOD CITY, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly p...

11 months ago - GlobeNewsWire